To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Neonatal encephalopathy (NE) is a clinical disorder of brain function that arises from various conditions impacting the central nervous system around the time of birth. Key symptoms include altered consciousness, respiratory depression, cranial nerve dysfunction, tone abnormalities, and seizures. The incidence of NE is estimated at 3 per 1,000 live births, with hypoxic–ischemic encephalopathy (HIE) accounting for approximately 1–1.5 per 1,000 live term births. Recent debates have centered around the definition and diagnosis of HIE, particularly concerning cerebral blood flow and oxygen delivery at birth. Identifying infants at high risk for evolving HIE is crucial, as therapeutic hypothermia, the only known treatment that can improve neurological outcomes, needs to be administered within 6 hours of birth. This chapter focuses on HIE as a distinct cause of NE, detailing its diagnosis and management, and discusses other conditions that may present with encephalopathy at different times post-delivery.
Hypoxic–ischemic encephalopathy (HIE) is a common cause of neonatal encephalopathy and requires careful and prompt diagnosis in order to initiate therapeutic hypothermia, a time-sensitive neuroprotective treatment. The clinical presentation is key in distinguishing HIE from other causes of neonatal encephalopathy and includes assessment of Apgar scores, physiologic markers of acute hypoxia such as the initial blood gas, the presence of an acute hypoxic–ischemic event, and exam findings consistent with a moderate or severe degree of encephalopathy. Specific eligibility criteria exist for each of these factors and are standardized across centers. Neurodiagnostic tools important for the evaluation and management of HIE include the electroencephalogram (EEG) and magnetic resonance imaging (MRI). EEG can help assess the degree of encephalopathy, provide early prognostic information, and detect subclinical seizures. The MRI is the gold standard imaging test to evaluate the location and degree of HIE injury and provide the most accurate information about long-term outcome.
Nearly all infants are exposed to repeated but usually short periods of compromised gas exchange before and during labor, and yet only a remarkably small proportion of newborns develop hypoxic–ischemic encephalopathy (HIE). Indeed, even severe metabolic acidosis at birth is associated with HIE in less than half of cases. Similarly, experimental studies typically report that cerebral injury occurs only in a very narrow temporal window between survival with complete recovery and death. In part, this reflects the remarkable efficacy of fetal adaptations that maintain perfusion to the essential organs. However, it also reflects a fine balance between injurious events triggered by hypoxia–ischemia and countervailing endogenous protective processes that help limit neural injury. These processes may be modified, raising the possibility of treating acute encephalopathy.
Inborn errors of metabolism and abnormalities in many single genes related to neuronal function can have clinical, biochemical, and neuroradiologic features similar to those of neonatal encephalopathy caused by environmental factors, such as in-utero hypoxia, ischemia, inflammation, or infection. Both genetic disorders and neonatal encephalopathy secondary to environmental factors, such as hypoxic–ischemic encephalopathy (HIE) or fetal inflammatory response syndrome, may be associated with severe neurologic distress, metabolic acidosis, brain imaging abnormalities, and multiorgan system involvement. Although newborn screening using tandem mass spectrometry (MS/MS) can detect numerous metabolic disorders, many inborn errors of metabolism that present with HIE-like features will be missed, so specialized biochemical tests or next-generation gene sequencing studies are required in order to establish a diagnosis. Prompt diagnosis of an underlying genetic disorder not only may prevent mortality or significant morbidity but also may allow the clinician to provide the family with comprehensive genetic counseling.
Perinatal brain injury is a significant contributor to cerebral palsy, epilepsy, and other neurological disorders, occurring from 20 weeks’ gestation to 28 days postnatally. Approximately 40% of cases are associated with premature birth, whereas 11% result from acute intrapartum hypoxia–ischemia (HI). Despite improvements in neonatal care, the incidence remains stable, underscoring the need for better early detection methods. There is a critical “window of opportunity” for therapeutic intervention postinsult, with therapeutic hypothermia being the only established neuroprotective therapy for term infants. However, its efficacy is limited, as many infants continue to suffer disabilities despite treatment. The development of robust biomarkers is essential to identify infants at risk for significant brain injury and to evaluate the effectiveness of treatments. This chapter explores existing and novel biomarkers for assessing injury, determining treatability, and predicting long-term outcomes after HI, ultimately aiming to enhance management strategies for affected infants and improve prognostic abilities in clinical practice.
After the initial resuscitation of a depressed or encephalopathic infant, the extended management of the patient becomes critical in order to prevent or ameliorate secondary injury. There are many different management protocols that are acceptable, and it is not the intent of this chapter to review all used for the various conditions encountered in neonatal intensive care. Rather, we focus on the early transitional period following birth and resuscitation for both the premature and term infant, during which the condition of the depressed infant can be substantially improved by expert care.
Neonatal encephalopathy (NE) encompasses a range of disorders presenting with altered brain function in neonates, often leading to long-term neurodevelopmental deficits. Characterized by symptoms such as altered consciousness, poor tone, and seizures, NE occurs in 1–6 per 1,000 live term births and is a major cause of neurodevelopmental disabilities. Although many cases relate to hypoxic–ischemic injury, other causes include metabolic disorders, infections, and congenital anomalies. The introduction of therapeutic hypothermia (TH) has improved outcomes for infants with hypoxic–ischemic encephalopathy (HIE), significantly reducing the incidence of severe neurodevelopmental disabilities. However, variations in practices and results persist, and adjunct therapies such as erythropoietin have not shown effective benefits. The chapter discusses the spectrum of neurocognitive impairments following HIE, predictors of outcomes based on brain injury patterns, and highlights ongoing research to understand the long-term impact of these interventions on affected individuals.
Neonatal encephalopathy (NE) is the term used to describe persistent neurological dysfunction evident in the first few days after birth. The commonest cause of NE is hypoxia-ischemia, but a similar clinical presentation may occur in other conditions. EEG is essential to grade the severity of neonatal encephalopathy, monitor response to anti-seizure therapy, and to predict outcome early in the neonatal period in infants with NE. Because therapeutic hypothermia is often used in neonatal encephalopathy, the impact of hypothermia on EEG findings is important to consider. EEG evolution and outcome prediction is altered by therapeutic hypothermia. Seizures are common in NE, and seizure burden is also altered by hypothermia. EEG and aEEG can assess severity of NE and predict outcome more accurately than clinical assessment alone. This chapter discusses the various uses of EEG and aEEG in neonatal encephalopathy.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.